Jim Jasper

Lupus Research Alliance and Lupus Therapeutics – Leading Voices in Trial Diversity

|

Caroline Donovan, Manager of Patient Engagement at Lupus Research Alliance (LRA) affiliate Lupus Therapeutics (LT) took part in a panel discussion at the DIA 2019 (Drug Information Association) annual meeting, aimed at finding ways to make sure that diverse groups of patients can make informed choices about joining a clinical trial. Ms. Donovan explained that … Lupus Research Alliance and Lupus Therapeutics – Leading Voices in Trial Diversity

VALUE Study Results Reported at EULAR

|

Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019.  Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a custom smartphone app effectively enabled lupus … VALUE Study Results Reported at EULAR

Taking Scientific Discovery: From Lab Bench to You

|

Making new and efficacious lupus therapies available to patients has long been a major focus of the Lupus Research Alliance, and today we’ve taken an important step toward that aim. Based on a breakthrough discovery made by Betty Diamond, MD of Feinstein Institutes for Medical Research, Meggan Mackay, MD, MS, also at Feinstein, will conduct a … Taking Scientific Discovery: From Lab Bench to You

Lupus Therapeutics Partners with Takeda to Test Potential Treatment for Lupus

|

The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916).  The national study will be conducted in 20 research centers throughout the country, many of which are members of … Lupus Therapeutics Partners with Takeda to Test Potential Treatment for Lupus

Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials

|

Today, Lupus Therapeutics, an affiliate of Lupus Research Alliance, is launching our Patient Advocates for Lupus Studies (PALS) program with a pilot study to determine its effectiveness in increasing awareness of and participation in lupus clinical trials, particularly among diverse populations.  The program will pair people with lupus interested in learning about trials with a … Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials

Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus

|

The Lupus Research Alliance announced that its affiliate Lupus Therapeutics is working with the pharmaceutical company, Janssen, to help conduct a Phase 3 trial to evaluate whether their drug ustekinumab (Stelara®) may offer benefit to people with lupus.  Called LOTUS, the international study is being conducted in over 200 sites, 20 of which are members … Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus

Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial

|

The Lupus Research Alliance today announced a collaboration between its newly formed affiliate, Lupus Therapeutics, and the pharmaceutical company, Bristol-Myers Squibb (BMS), to test a novel investigational drug, BMS-986165, as a potential new therapy for lupus. The first of its kind to be tested in lupus, BMS-986165 is a potent and highly selective inhibitor of … Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial

Lupus Research Alliance LuCIN Clinical Trials Network Launches Inaugural Studies

|

The Lupus Research Alliance today announced the first clinical trials to be conducted through its Lupus Clinical Investigators Network (LuCIN) aimed at discovering new treatments for the millions of people around the globe living with lupus. Recognizing the limited treatments for lupus, LuCIN was organized, managed and is funded by the Lupus Research Alliance to … Lupus Research Alliance LuCIN Clinical Trials Network Launches Inaugural Studies

New Smartphone App VALUE May Enable Lupus Patients to Report Symptoms Easily and Accurately

|

The Lupus Research Alliance, the world’s largest private funder of lupus research, and Pfizer Inc., the global biopharmaceutical company, announced the start of a non-interventional clinical study that will test a custom smartphone app enabling lupus patients to report on their fatigue and other symptoms in real time. Incorporating feedback from people with lupus, the … New Smartphone App VALUE May Enable Lupus Patients to Report Symptoms Easily and Accurately

Lupus Research Alliance Launches Clinical Trial Network

|

The Lupus Research Alliance launched a bold initiative, the Lupus Clinical Investigators Network (LuCIN) to accelerate the identification and development of new therapies to treat lupus. Comprised of leading lupus experts at 58 academic research centers throughout North America, LuCIN provides a coordinated framework to test potential new treatments quickly and cost-effectively while upholding the highest scientific standards. Investigators are … Lupus Research Alliance Launches Clinical Trial Network